Tuesday, August 24, 2021 8:50:51 AM
SAVA up 9% premarket 
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
http://ih.advfn.com/stock-market/NASDAQ/cassava-sciences-SAVA/stock-news/85901842/cassava-sciences-announces-agreement-with-fda-on-s
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease http://ih.advfn.com/stock-market/NASDAQ/cassava-sciences-SAVA/stock-news/85901842/cassava-sciences-announces-agreement-with-fda-on-s
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
